Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 41 of 102, showing 5 Applications out of 508 total, starting on record 201, ending on 205

# Protocol No Study Title Investigator(s) & Site(s)

201.

ECCT/24/01/01   SAVIS
    A Phase 1 Clinical Study to Evaluate the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoidal Salmonella in healthy Kenyan adults.      
Principal Investigator(s)
1. ANTHONY SCOTT
Site(s) in Kenya
KEMRI Centre for Geographical Medicine Research Coast
 
View

202.

ECCT/20/10/03   Commercial Typhoid tests valid
    Comparative study of commercially available typhoid point of care tests to benchmark current and emerging tools   
Principal Investigator(s)
1. Robert Sanaya Onsare
Site(s) in Kenya
1. Mbagathi County Hospital (Nairobi City county)
2. Medical Missionaries of Mary, Reuben Centre Hospital, Mukuru (Nairobi City county)
3. City Council Clinic, Mukuru (Nairobi City county)
 
View

203.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
View

204.

ECCT/19/03/02   PREVENT TD
    A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg daily or 550 mg twice daily) for Chemoprophylaxis Against Travellers’ Diarrhoea (TD) Among Active Duty Deployed U.S. and British Military Personnel (PREVENT TD)   
Principal Investigator(s)
1. Flynn Alexander
Site(s) in Kenya
Nyati Barracks, British Army Training Unit, Kenya
 
View

205.

ECCT/21/09/03   Women TDF/FTC Benchmark Study
    Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women   
Principal Investigator(s)
1. Nelly Mugo
Site(s) in Kenya
KEMRI-CCR PHRD (THIKA) PROJECT
 
View